Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.6460 -0.0440 (-6.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,680
Open 0.6936
Bid (Size) 0.6460 (2)
Ask (Size) 0.7000 (2)
Prev. Close 0.6900
Today's Range 0.6460 - 0.7100
52wk Range 0.4728 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
From ZyVersa Therapeutics
Via GlobeNewswire

Performance

YTD
-40.7%
-40.7%
1 Month
+17.5%
+17.5%
3 Month
-13.3%
-13.3%
6 Month
-43.3%
-43.3%
1 Year
-86.6%
-86.6%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps
Via Stocktwits
These stocks that are showing activity before the opening bell on Wednesday.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
The market is filled with gapping stocks in Wednesday's session.
Via Chartmill
Which stocks are moving on Tuesday?
Via Chartmill
Tuesday's session: most active stocks
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is ZyVersa Therapeutics, Inc. - Common Stock publicly traded?
Yes, ZyVersa Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does ZyVersa Therapeutics, Inc. - Common Stock trade on?
ZyVersa Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ZyVersa Therapeutics, Inc. - Common Stock?
The ticker symbol for ZyVersa Therapeutics, Inc. - Common Stock is ZVSA on the Nasdaq Stock Market
What is the current price of ZyVersa Therapeutics, Inc. - Common Stock?
The current price of ZyVersa Therapeutics, Inc. - Common Stock is 0.6460
When was ZyVersa Therapeutics, Inc. - Common Stock last traded?
The last trade of ZyVersa Therapeutics, Inc. - Common Stock was at 06/20/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.